(NASDAQ: ROIV) Roivant Sciences's forecast annual revenue growth rate of 457.31% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.79%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Roivant Sciences's revenue in 2026 is $8,260,000.On average, 14 Wall Street analysts forecast ROIV's revenue for 2027 to be $64,985,360,014, with the lowest ROIV revenue forecast at $10,322,249,295, and the highest ROIV revenue forecast at $235,035,983,706. On average, 12 Wall Street analysts forecast ROIV's revenue for 2028 to be $304,798,018,348, with the lowest ROIV revenue forecast at $83,881,312,299, and the highest ROIV revenue forecast at $647,515,971,392.
In 2029, ROIV is forecast to generate $1,147,955,534,460 in revenue, with the lowest revenue forecast at $874,632,788,160 and the highest revenue forecast at $1,544,992,786,980.